Clinical Trial Update: The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling [Phase 4]

View source ↗

Summary

This Phase 4 trial update examines how different doses of valsartan and a genetic polymorphism influence post-myocardial infarction ventricular remodeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• DIOVAN (valsartan)

Snippet

Sponsor: Dong-A University | Conditions: Myocardial Infarction | Phase 4 | Status: COMPLETED